HRP20182138T1 - Modificirani serpini za liječenje poremećaja s krvarenjem - Google Patents

Modificirani serpini za liječenje poremećaja s krvarenjem

Info

Publication number
HRP20182138T1
HRP20182138T1 HRP20182138TT HRP20182138T HRP20182138T1 HR P20182138 T1 HRP20182138 T1 HR P20182138T1 HR P20182138T T HRP20182138T T HR P20182138TT HR P20182138 T HRP20182138 T HR P20182138T HR P20182138 T1 HRP20182138 T1 HR P20182138T1
Authority
HR
Croatia
Prior art keywords
treatment
blood disorder
modified serpins
serpins
modified
Prior art date
Application number
HRP20182138TT
Other languages
English (en)
Croatian (hr)
Inventor
James Andrew HUNTINGTON
Stéphanie POLDERDIJK
Trevor Baglin
Original Assignee
Cambridge Enterprise Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Limited filed Critical Cambridge Enterprise Limited
Publication of HRP20182138T1 publication Critical patent/HRP20182138T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0015—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028—Polypeptides; Proteins; Degradation products thereof
    • A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/04—Materials for stopping bleeding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
HRP20182138TT 2013-12-13 2014-12-15 Modificirani serpini za liječenje poremećaja s krvarenjem HRP20182138T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1322091.8A GB201322091D0 (en) 2013-12-13 2013-12-13 Modified serpins for the treatment of bleeding disorders
EP14827185.1A EP3080157B1 (en) 2013-12-13 2014-12-15 Modified serpins for the treatment of bleeding disorders
PCT/EP2014/077783 WO2015086854A1 (en) 2013-12-13 2014-12-15 Modified serpins for the treatment of bleeding disorders

Publications (1)

Publication Number Publication Date
HRP20182138T1 true HRP20182138T1 (hr) 2019-02-08

Family

ID=50030900

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20182138TT HRP20182138T1 (hr) 2013-12-13 2014-12-15 Modificirani serpini za liječenje poremećaja s krvarenjem

Country Status (25)

Country Link
US (2) US9982035B2 (enExample)
EP (2) EP3080157B1 (enExample)
JP (2) JP6431541B2 (enExample)
KR (2) KR102186924B1 (enExample)
CN (2) CN110330563B (enExample)
AU (2) AU2014363359B2 (enExample)
CA (1) CA2933508C (enExample)
CY (1) CY1121267T1 (enExample)
DK (1) DK3080157T3 (enExample)
EA (1) EA034050B1 (enExample)
ES (1) ES2704058T3 (enExample)
GB (1) GB201322091D0 (enExample)
HR (1) HRP20182138T1 (enExample)
HU (1) HUE042763T2 (enExample)
IL (2) IL246180B (enExample)
LT (1) LT3080157T (enExample)
MX (1) MX357941B (enExample)
NZ (1) NZ721918A (enExample)
PL (1) PL3080157T3 (enExample)
PT (1) PT3080157T (enExample)
RS (1) RS58191B1 (enExample)
SI (1) SI3080157T1 (enExample)
SM (1) SMT201900016T1 (enExample)
TR (1) TR201819781T4 (enExample)
WO (1) WO2015086854A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100183558A1 (en) 2008-10-17 2010-07-22 Zhennan Lai Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
GB201322091D0 (en) 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
WO2017007994A1 (en) 2015-07-08 2017-01-12 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
CN111569090A (zh) 2016-01-15 2020-08-25 美国基因技术国际有限公司 用于活化γ-δ T细胞的方法和组合物
JP7153332B2 (ja) 2016-02-08 2022-10-14 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Ｈｉｖワクチン接種および免疫療法
ES2911448T3 (es) 2016-03-09 2022-05-19 American Gene Tech Int Inc Vectores combinados y métodos para el tratamiento del cáncer
US11976292B2 (en) 2016-06-08 2024-05-07 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
EP3481418A4 (en) 2016-07-08 2020-03-11 American Gene Technologies International Inc. PRE-IMMUNIZATION AND IMMUNOTHERAPY OF HIV
EP3585808B1 (en) 2017-02-23 2021-11-10 Preclinics Gesellschaft für präklinische Forschung mbH Modified serpins for the treatment of bradykinin-mediated disease
JP2020512815A (ja) 2017-04-03 2020-04-30 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド フェニルケトン尿症を処置するための組成物および方法
RU2663464C1 (ru) * 2018-02-26 2018-08-06 Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" Комбинаторная терапия для лечения геморрагического шока
CA3117961A1 (en) * 2018-10-29 2020-05-07 Spin Therapeutics, Llc Compositions and methods for alpha-1-antitrypsin disorders
CN110051830A (zh) * 2019-03-14 2019-07-26 苏州新凝生物医药科技有限公司 一种protease nexin II\KPI蛋白突变体的应用
WO2022226451A1 (en) * 2021-04-20 2022-10-27 University Of Louisville Recombinant miropin
US20250066436A1 (en) 2021-12-22 2025-02-27 Royal College Of Surgeons In Ireland A conjugate for use in localising a molecule to the vascular endothelium
EP4707391A1 (en) * 2024-09-10 2026-03-11 e-therapeutics PLC Nucleic acid compounds for zpi inhibition

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711848A (en) 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
FR2599752B1 (fr) 1986-06-10 1989-11-03 Transgene Sa Variants de l'alpha1- antitrypsine utiles notamment comme inhibiteurs de la kallikreine
DE3705745A1 (de) 1987-02-23 1988-09-01 Behringwerke Ag Protein c-inhibitor (pci) als pharmazeutikum und in vitro-diagnostikum, verfahren zur herstellung eines solchen pharmazeutikums oder diagnostikums sowie ein mittel enthaltend pci
US5612194A (en) 1989-06-23 1997-03-18 Trustees Of The University Of Pennsylvania Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors
IE902276A1 (en) 1989-06-26 1991-01-16 Akzo Nv Serpin variants
CA2272095A1 (en) 1996-11-19 1998-05-28 Saulius Butenas Peptidomimetics containing 6-peptidylamino-1-naphthalenesulfonamide moieties
WO2001055390A1 (en) 2000-01-28 2001-08-02 Human Genome Sciences, Inc. Human serpin polynucleotides, polypeptides, and antibodies
JP2002010783A (ja) 2000-06-29 2002-01-15 Jcr Pharmaceuticals Co Ltd 改変型ヒトプロテインｃインヒビター
US6924267B2 (en) 2001-09-18 2005-08-02 Suomen Punainen Risti Veripalvelu Methods and active substances for protecting organs
JP2003093063A (ja) 2001-09-20 2003-04-02 Jcr Pharmaceuticals Co Ltd 改変型ヒトプロテインｃインヒビター
WO2003039585A1 (en) 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors
FR2836143B1 (fr) 2002-02-21 2004-04-16 Servier Lab Nouveaux derives d'acides amines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2004056309A2 (en) 2002-12-05 2004-07-08 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
ES2504365T3 (es) 2002-12-05 2014-10-08 Zz Biotech L.L.C. La actividad neuroprotectora de la proteína C activada es independiente de su actividad anticoagulante
WO2006090282A2 (en) * 2005-02-28 2006-08-31 Universite De Lausanne Recombinant inhibitor proteins of an hk14 protease and use thereof
US8106002B2 (en) 2005-04-18 2012-01-31 Chugai Seiyaku Kabushiki Kaisha Anti-cancer agent comprising protein C inhibitor
EP1960266B1 (en) * 2005-12-15 2019-02-20 Gulfstream Aerospace Corporation Isentropic compression inlet for supersonic aircraft
NZ596269A (en) 2006-07-05 2012-12-21 Catalyst Biosciences Inc Protease screening methods and proteases identified thereby
EP2081589B1 (en) 2006-11-16 2010-10-06 Crucell Holland B.V. Complementation of factor xi deficiency by factor v mutants
WO2008059043A2 (en) 2006-11-16 2008-05-22 Crucell Holland B.V. Combination of coagulation factor viii with apc-resistant factor v
WO2008059009A2 (en) 2006-11-16 2008-05-22 Crucell Holland B.V. Factor v mutants for hemostasis in hemophilia
DK2175877T3 (da) 2007-07-20 2012-04-16 Univ Paris Sud Xi Anvendelse af muterede antitrombiner til behandling eller forebyggelse af koagulationssygdomme
GB0714649D0 (en) 2007-07-27 2007-09-05 Univ Leuven Kath Novel viral replication inhibitors
MX2010004615A (es) 2007-10-26 2010-07-06 Oklahoma Med Res Found Anticuerpos monoclonales contra proteina c. activada e inactivada.
EP2055783A1 (en) * 2007-10-30 2009-05-06 VIB vzw Insect inhibiting plant serpin mutants
JP2011502478A (ja) 2007-11-01 2011-01-27 ユニバーシティー オブ ロチェスター 安定性が増大した組換え型第ｖｉｉｉ因子
US20110130338A1 (en) * 2008-01-21 2011-06-02 Dermadis Sa Use of serine protease inhibitors in the treatment of skin diseases
WO2010081878A1 (en) 2009-01-16 2010-07-22 Universite Paris-Sud Xi Mutated antithrombins, a process for preparing the same and their use as drugs
EP2423233B1 (en) * 2009-04-22 2015-03-11 Alteogen, Inc In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasing in vivo half-life using same
US8557961B2 (en) * 2010-04-02 2013-10-15 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
CN105431165A (zh) 2013-05-15 2016-03-23 莫尔研究应用有限公司 用于治疗心肺手术后的术后并发症的组合物和方法
GB201322091D0 (en) 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
EP3585808B1 (en) * 2017-02-23 2021-11-10 Preclinics Gesellschaft für präklinische Forschung mbH Modified serpins for the treatment of bradykinin-mediated disease

Also Published As

Publication number Publication date
JP6723319B2 (ja) 2020-07-15
DK3080157T3 (en) 2018-12-17
IL246180B (en) 2018-11-29
SI3080157T1 (sl) 2018-12-31
AU2018279054A1 (en) 2019-01-17
US10351619B2 (en) 2019-07-16
CA2933508A1 (en) 2015-06-18
US20160311887A1 (en) 2016-10-27
KR101954945B1 (ko) 2019-03-07
KR102186924B1 (ko) 2020-12-04
CN105992771A (zh) 2016-10-05
KR20190022945A (ko) 2019-03-06
ES2704058T3 (es) 2019-03-14
CN110330563A (zh) 2019-10-15
CY1121267T1 (el) 2020-05-29
TR201819781T4 (tr) 2019-01-21
PT3080157T (pt) 2019-01-11
MX2016007711A (es) 2016-12-09
BR112016013591A2 (pt) 2017-10-03
EA201691235A1 (ru) 2016-12-30
SMT201900016T1 (it) 2019-02-28
JP2017505114A (ja) 2017-02-16
EP3080157A1 (en) 2016-10-19
EP3434689A1 (en) 2019-01-30
HUE042763T2 (hu) 2019-07-29
RS58191B1 (sr) 2019-03-29
JP6431541B2 (ja) 2018-11-28
MX357941B (es) 2018-07-31
KR20160092025A (ko) 2016-08-03
IL246180A0 (en) 2016-07-31
EP3080157B1 (en) 2018-10-03
LT3080157T (lt) 2018-12-10
US9982035B2 (en) 2018-05-29
AU2014363359A1 (en) 2016-07-21
GB201322091D0 (en) 2014-01-29
IL262879A (en) 2018-12-31
EA034050B1 (ru) 2019-12-23
PL3080157T3 (pl) 2019-03-29
CN105992771B (zh) 2019-08-23
CA2933508C (en) 2021-04-06
US20180273610A1 (en) 2018-09-27
JP2019037242A (ja) 2019-03-14
AU2014363359B2 (en) 2019-01-03
CN110330563B (zh) 2024-03-29
WO2015086854A1 (en) 2015-06-18
NZ721918A (en) 2019-12-20

Similar Documents

Publication Publication Date Title
EP2968191A4 (en) METHOD FOR THE TREATMENT OF BUBBLE CANCER
EP2968208A4 (en) TREATMENT OF CATAPLEXIA
IL290994A (en) Methods of diagnosing and treating conduct disorder
EP3011515A4 (en) LANGUAGE TRANSACTION PROCESSING
PL3076967T3 (pl) Metody leczenia objawów rezydualnych schizofrenii
EP2890806A4 (en) PROCESSING BIOMASS
LT2885010T (lt) Tautopatijos gydymo būdai
LT3277842T (lt) Vėžio pacientų gydymo būdai farneziltransferazės inhibitoriais
HRP20260139T1 (hr) Farmaceutski pripravak, postupci za liječenje i njegove uporabe
PL3542798T3 (pl) Aceklidyna do zastosowania w leczeniu starczowzroczności
SI3033086T1 (sl) Kombinirana terapija za zdravljenje raka
HUE056287T2 (hu) Pancreatitis kezelése
LT2981255T (lt) Empagliflozino terapiniai panaudojimo būdai
PT3626270T (pt) Tratamento de doenças cardiovasculares
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
LT3007726T (lt) Tautopatijos gydymo būdai
DK2764881T3 (da) System til medicinsk behandling
HUE042763T2 (hu) Módosított szerpinek vérzési rendellenességek kezelésére
IL247354A0 (en) Treatment of conditions associated with hyperinsulinaemia
DK2961378T3 (da) Fremgangsmåder til behandlingen af mitochondrisk sygdom
HRP20180337T1 (hr) Kalcitonin mimetika za liječenje bolesti i poremećaja
HUE061493T2 (hu) Vetõmagok fertõtlenítõ kezelése
FI20135866L (fi) Mikrobiologinen keratiinin prosessointi
LT2958624T (lt) Transplantuotų pacientų transplantanto prieš šeiminiką ligos gydymas
IL254825A0 (en) Methods of treatment with taselisib